Straumann Holding AG (SAUHF) Stock

About Straumann Holding AG

Straumann Holding AG is a global provider of dental solutions, specializing in restoring and correcting teeth. The company is actively involved in the research, development, production, and distribution of a comprehensive portfolio of dental products. These include advanced dental implants, specialized instruments, CAD/CAM-designed prosthetics, clear orthodontic aligners, biomaterials, and various digital tools. These offerings are designed to address tooth correction, replacement, and restoration, alongside preventative dental care. Its extensive product range features diverse dental implant systems, available in both tissue and bone-level designs and crafted from materials like titanium, titanium alloy, or ceramic, including specialized mini implants. Straumann also supplies both guided and non-guided surgical instrument sets, along with prosthetics designed for integration with implants. Beyond implants, the company provides ceramic healing and screw-retained abutments, cutting-edge intraoral scanning devices, 3D printers, and milling machines, as well as preventative dental care products. Furthermore, Straumann is a provider of biomaterials such as bone substitutes, regenerative membranes, biologics, and solutions for soft tissue management and oral healing. Its digital solutions cater to dental laboratories, practitioners, and centralized milling facilities, encompassing specialized materials, third-party system integration, and guided surgery platforms. The surgical instrument range is comprehensive, featuring various cassettes (surgical and modular), guided instrumentation, implant maintenance tools, bone block fixation kits, bone rings, and titanium pin sets. For patients who have lost all their teeth (edentulous patients), Straumann provides a variety of solutions, including pro arch fixed restorations, advanced prosthetics, and mini implant systems. The company also offers aesthetic restoration options, such as ceramic implant monotypes, ceramic implants, cosmetic abutments, and biologics. Its portfolio also includes Emdogain, a product specifically designed for wound healing. Straumann additionally markets Clear Correct aligners for orthodontic treatment and provides extensive training and educational programs for its clientele. Its diverse customer base includes general dentists, dental specialists, and dental technicians/laboratories, along with corporate clients like distributors, hospitals, universities, and dental service organizations. Straumann distributes its products and services across roughly 100 countries, leveraging a robust network of distribution subsidiaries and strategic partners. Established in 1954, Straumann Holding AG maintains its corporate headquarters in Basel, Switzerland.

Straumann Holding AG is headquartered in CH.

Straumann Holding AG (SAUHF) stock trades at $130.77 with a market capitalization of $20.85B. The stock is valued at a price-to-earnings (P/E) ratio of 45.53, price-to-book of 7.51, price-to-sales of 6.27. Over the past 52 weeks the stock has ranged between $93.18 and $139.55, and currently trades 6.3% below its 52-week high. It pays a dividend yielding 1.24%.

On profitability, Straumann Holding AG generates a return on equity (ROE) of 16.90%, above the typical market average, return on capital employed of 17.50%, an operating margin of 20.65%, a net profit margin of 13.68%.

In its most recent fiscal year, Straumann Holding AG reported annual revenue of $2.6B, net profit of $358.0M, revenue has compounded at 12.8% a year over the last five years, profit at 31.5% a year. Profit growing faster than revenue points to expanding margins.

The balance sheet shows a debt-to-equity ratio of 0.30 — a conservative balance sheet with little leverage risk, a current ratio of 2.21, total assets of $3.8B, $476.0M in cash and equivalents.

SAUHF has an average daily trading volume of 383 shares, a beta of 1.39 (more volatile than the overall market).

Official website: www.straumann.com